MicrobeWorld App

appsquarebannerad200x200

Microbes After Hours

MWbannerEbola

Click for more "Microbes After Hours" videos

Join MicrobeWorld

Subscribe via Email

subscribe

Featured Image

Featured Video

Ebola Virus explained

Supporters

ASM House 200X200

Data sharing aids the fight against malaria

Image
In the hunt for drugs that target diseases in the developing world, ‘open innovation’ is creating a buzz. Pharmaceutical companies are making entire libraries of chemical compounds publicly available, allowing researchers to rifle through them for promising drug candidates.

The latest push for open innovation, unveiled last month as part of a World Health Organization road map to control neglected tropical diseases, will see 11 companies sharing their intellectual property to give researchers around the world a head start on investigating drug leads (see 'Road map unveiled to tackle neglected diseases' - http://www.nature.com/news/road-map-unveiled-to-tackle-neglected-diseases-1.9938). It makes for good press, and investors are not worried about giving away potentially blockbuster drugs because the diseases in question are not commercial priorities.

But is it good science? The answer, from the first large-scale initative of this kind, is a cautious 'yes'.
 
 

Comments (0)

Collections (0)

 

American Society for Microbiology
2012 1752 N Street, N.W. • Washington, DC 20036-2904 • (202) 737-3600
American Society For Microbiology © 2014   |   Privacy Policy   |   Terms of Use